{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:41:54Z","timestamp":1792676514044,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neurol.2026.02.155","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:57:15Z","timestamp":1775055435000},"page":"428-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adaptive trials and new designs"],"prefix":"10.1016","volume":"182","author":[{"given":"C.","family":"Wade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Apap Mangion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chataway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2026.02.155_bib0130","doi-asserted-by":"crossref","first-page":"e064169","DOI":"10.1136\/bmjopen-2022-064169","article-title":"Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensus","volume":"13","author":"Wong","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.neurol.2026.02.155_bib0135","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40265-021-01526-w","article-title":"Failed, interrupted, or inconclusive trials on neuroprotective and neuroregenerative treatment strategies in multiple sclerosis: update 2015\u20132020","volume":"81","author":"Huntemann","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.neurol.2026.02.155_bib0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1474-4422(24)00027-9","article-title":"Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges","volume":"23","author":"Chataway","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.02.155_bib0145","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1186\/s13063-022-06588-z","article-title":"Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials","volume":"23","author":"Williams","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.neurol.2026.02.155_bib251","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1474-4422(19)30485-5","article-title":"Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial","volume":"19","author":"Chataway","year":"2020","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.neurol.2026.02.155_bib0155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.euroneuro.2010.09.003","article-title":"Adaptive design clinical trials and trial logistics models in CNS drug development","volume":"21","author":"Wang","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.neurol.2026.02.155_bib0160","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa1716405","article-title":"Tenecteplase versus alteplase before thrombectomy for ischemic stroke","volume":"378","author":"Campbell","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.02.155_bib0165","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1212\/01.WNL.0000286940.29755.61","article-title":"Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine","volume":"70","author":"Ho","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.02.155_bib0170","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/brain\/awac005","article-title":"Smarter adaptive platform clinical trials in neurology","volume":"145","author":"Husain","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2026.02.155_bib0175","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1474-4422(21)00388-4","article-title":"Trials for neurodegenerative diseases: time to innovate","volume":"20","author":"Mehta","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.02.155_bib0180","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/jnnp-2020-324286","article-title":"Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis","volume":"92","author":"Cunniffe","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.02.155_bib0185","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1042\/CS20220494","article-title":"Systematic online living evidence summaries: emerging tools to accelerate evidence synthesis","volume":"137","author":"Hair","year":"2023","journal-title":"Clin Sci"},{"key":"10.1016\/j.neurol.2026.02.155_bib0190","doi-asserted-by":"crossref","DOI":"10.1002\/sim.70245","article-title":"Impact of endpoint delay on the efficiency of multi arm multi stage trials","volume":"44","author":"Mukherjee","year":"2025","journal-title":"Stat Med"},{"key":"10.1016\/j.neurol.2026.02.155_bib0195","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1186\/s13063-024-08400-6","article-title":"Design considerations for Factorial Adaptive Multi-Arm Multi-Stage (FAST) clinical trials","volume":"25","author":"Beall","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.neurol.2026.02.155_bib0200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/sim.9961","article-title":"A flexible multi-metric Bayesian framework for decision-making in phase II multi-arm multi-stage studies","volume":"43","author":"Dufault","year":"2024","journal-title":"Stat Med"},{"key":"10.1016\/j.neurol.2026.02.155_bib0205","doi-asserted-by":"crossref","first-page":"e2221140","DOI":"10.1001\/jamanetworkopen.2022.21140","article-title":"Economic evaluation of cost and time required for a platform trial vs. conventional trials","volume":"5","author":"Park","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.neurol.2026.02.155_bib0210","doi-asserted-by":"crossref","first-page":"e055615","DOI":"10.1136\/bmjopen-2021-055615","article-title":"Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials","volume":"12","author":"Noor","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.neurol.2026.02.155_bib0215","unstructured":"MRC Clinical Trials Unit. Multi-Arm Multi-Stage (MAMS) trials [online]. Accessed at: https:\/\/www.mrcctu.ucl.ac.uk\/our-research\/methodology\/design\/multi-arm-multi-stage-mams-platform-trials\/. Accessed November 19, 2025."},{"key":"10.1016\/j.neurol.2026.02.155_bib0220","unstructured":"MRC Clinical Trials Unit. ACORD Collaboration [online]. Accessed at: https:\/\/www.mrcctu.ucl.ac.uk\/our-research\/neurodegenerative-diseases\/acord-collaboration\/. Accessed November 24, 2025."},{"key":"10.1016\/j.neurol.2026.02.155_bib0225","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S1474-4422(24)00326-0","article-title":"Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial","volume":"23","author":"Pal","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.02.155_bib0230","unstructured":"Accelerating Clinical Trials in Parkinson's\u00a0\u2013\u00a0the Edmond J Safra ACT-PD Trial. The EJS ACT PD Trial [online]. Accessed at: https:\/\/www.ejsactpd.com. Accessed November 19, 2025."},{"key":"10.1016\/j.neurol.2026.02.155_bib0235","unstructured":"Imperial College London. AD SMART [online]. Accessed at: https:\/\/popped.org.uk\/ad-smart-2\/. Accessed November 23, 2025."},{"key":"10.1016\/j.neurol.2026.02.155_bib0240","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ana.24018","article-title":"Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis","volume":"75","author":"Sormani","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.02.155_bib0245","doi-asserted-by":"crossref","first-page":"1254303","DOI":"10.3389\/fncel.2023.1254303","article-title":"activator metformin improves recovery from demyelination by shifting oligodendrocyte bioenergetics and accelerating OPC differentiation","volume":"17","author":"Narine","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurol.2026.02.155_bib0250","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000374","article-title":"Lipoic acid in secondary progressive MS","volume":"4","author":"Spain","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726004650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726004650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:14:46Z","timestamp":1792674886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726004650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0035378726004650"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.02.155","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adaptive trials and new designs","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.02.155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}